| |
| |
|
| Insider
Information: |
Duncan Barbara Gayle |
| Relationship: |
|
| City: |
Somerset |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
61,571 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,155,261 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
61,571 |
|
|
| Total
Value |
$1,155,261 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Innoviva Inc |
INVA |
Director |
2017-04-20 |
52,318 |
2016-11-18 |
0 |
Premium* |
|
|
Aevi Genomic Medicine Inc |
GNMX |
Director |
2020-02-03 |
0 |
2017-10-17 |
0 |
Premium* |
|
|
Jounce Therapeutics Inc |
JNCE |
Director |
2020-09-15 |
0 |
2018-01-26 |
0 |
Premium* |
|
|
Immunomedics Inc |
IMMU |
Director |
2020-10-23 |
0 |
2019-06-07 |
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
|
2023-05-05 |
9,253 |
2023-02-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
18 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HALO |
Halozyme Therapeutics Inc |
|
– • – |
2023-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
8,065 |
9,253 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
|
– • – |
2023-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,188 |
1,188 |
0 |
- |
|
| IMMU |
Immunomedics Inc |
Director |
– • – |
2020-10-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(49,244) |
0 |
0 |
- |
|
| JNCE |
Jounce Therapeutics Inc |
Director |
– • – |
2020-09-15 |
4 |
AS |
$9.50 |
$100,000 |
D/D |
(10,000) |
0 |
0 |
% |
|
| JNCE |
Jounce Therapeutics Inc |
Director |
– • – |
2020-09-15 |
4 |
OE |
$4.21 |
$42,100 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| IMMU |
Immunomedics Inc |
Director |
– • – |
2020-09-14 |
4 |
OE |
$16.96 |
$42,400 |
D/D |
2,500 |
39,577 |
0 |
- |
|
| IMMU |
Immunomedics Inc |
Director |
– • – |
2020-08-17 |
4 |
OE |
$16.96 |
$339,200 |
D/D |
20,000 |
37,077 |
0 |
- |
|
| IMMU |
Immunomedics Inc |
Director |
– • – |
2020-08-12 |
4 |
OE |
$12.93 |
$220,806 |
D/D |
17,077 |
17,077 |
0 |
- |
|
| IMMU |
Immunomedics Inc |
Director |
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
3,718 |
13,385 |
0 |
- |
|
| GNMX |
Aevi Genomic Medicine Inc |
Director |
– • – |
2020-02-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(59,524) |
0 |
0 |
- |
|
| IMMU |
Immunomedics Inc |
Director |
– • – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
9,667 |
9,667 |
0 |
- |
|
| JNCE |
Jounce Therapeutics Inc |
Director |
– • – |
2018-03-15 |
4 |
AS |
$28.11 |
$56,220 |
D/D |
(2,000) |
0 |
0 |
- |
|
| JNCE |
Jounce Therapeutics Inc |
Director |
– • – |
2018-03-15 |
4 |
OE |
$4.21 |
$8,420 |
D/D |
2,000 |
2,000 |
0 |
- |
|
| JNCE |
Jounce Therapeutics Inc |
Director |
– • – |
2018-01-26 |
4 |
AS |
$25.00 |
$100,000 |
D/D |
(4,000) |
0 |
0 |
- |
|
| JNCE |
Jounce Therapeutics Inc |
Director |
– • – |
2018-01-26 |
4 |
OE |
$4.21 |
$16,840 |
D/D |
4,000 |
4,000 |
0 |
- |
|
| GNMX |
Aevi Genomic Medicine Inc |
Director |
– • – |
2017-10-17 |
4 |
B |
$1.26 |
$75,000 |
D/D |
59,524 |
59,524 |
2.39 |
- |
|
| INVA |
Innoviva Inc |
Director |
– • – |
2017-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
19,857 |
52,318 |
0 |
- |
|
| INVA |
Innoviva Inc |
Director |
– • – |
2016-11-18 |
4 |
A |
$0.00 |
$0 |
D/D |
32,461 |
32,461 |
0 |
- |
|
18 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
